July 8, 2016 (Waterloo, Ontario) – Intellijoint Surgical® – a privately held Canadian medical technology company committed to developing and commercializing affordable 3D mini-optical navigation tools – is pleased to announce the first successful clinical use of the Direct Anterior Approach (DAA) Application of intellijoint HIP®. DAA is a minimally invasive surgical technique that approaches Total Hip Arthroplasty (THA) through a small incision made on the front of the hip.
The first clinical use of intellijoint HIP DAA Application was completed on Tuesday, July 5, 2016 at London Health Sciences Centre by orthopaedic surgeon and DAA expert Dr. Brent Lanting. Dr. Lanting performed a successful THA using the direct anterior approach with intellijoint HIP DAA Application, a surgical navigation tool that provides real-time intraoperative measurements to assist in proper implant size selection and positioning.
“Completion of the first clinical procedure using intellijoint HIP DAA Application solidifies our commitment to providing advanced tools for hip replacement surgery. These tools can improve clinical outcomes by ensuring proper alignment and positioning to ultimately reduce readmissions and the need for revisions,” said Armen Bakirtzian, Co-Founder and CEO of Intellijoint Surgical.
DAA is a more difficult surgical technique for hip replacement that works around the muscles instead of detaching them. Studies indicate that because it is minimally invasive, patients are able to heal quickly and be back on their feet faster.
“The learning curve for DAA can be steep and requires significant amounts of fluoroscopy (radiation) during surgery. We believe that intellijoint HIP DAA Application can accelerate the learning curve, while reducing the intraoperative fluoroscopy needed, therefore limiting radiation exposure to the patient and surgeon,” commented Andre Hladio, Chief Technology Officer and Co-Founder of Intellijoint Surgical.
intellijoint HIP’s use for direct anterior approach during a Total Hip Arthroplasty is currently in a limited market release in Canada and not yet cleared by the FDA.